Microglia, the resident immune cells of the brain, are key players in maintaining homeostasis in the brain. One of their main functions is the removal of apoptotic cells generated during development, in adult neurogenic niches and in neurodegenerative diseases to prevent the spillover of toxic contents. However, this key mechanism of brain repair it has not been exploited as a therapeutic target yet. This talk will be focused on two main issues that are slowing research on microglial phagocytosis as a therapeutic target: The lack of compounds capable of modulating phagocytosis and the lack of readily available human microglia to develop humanized models of disease where these compounds can be tested.
In order to tackle the first issue, we have optimized a high throughput screening of drugs. We have used the Prestwick library of drugs, which are compounds pre-approved by the FDA and EMA and our in-house in vitro model of phagocytosis where murine primary microglia are fed apoptotic cells. To distinguish between effects on engulfment and degradation, two different drug administration paradigms were used: pre-incubation with the compounds followed by co-incubation with apoptotic cells to test engulfment; and co-incubation with apoptotic cells followed by washing and adding the compounds to test degradation. Using this optimized in vitro phagocytosis model, we found several compounds capable of modulating the phagocytic activity of microglia that we are currently validating in organotypic slice cultures.
To address the second issue, I will focus on the generation of monocultured microglia-like cells derived from human induced pluripotent stem cells (iPSC) to overcome the intrinsic limitations of culturing primary mouse microglia. During my time at Roche we described a protocol for the generation of microglia-like cells from human iPSC. Our starting point was an established differentiation protocol to generate primitive macrophage precursors from Sally Cowley“s lab in Oxford University (UK). We tested 36 differentiation conditions for the cells in monoculture where we exposed them to various combinations of media, morphogens, and extracellular matrices. The optimized protocol generated robustly ramified cells expressing key microglial markers. Bulk mRNA sequencing expression profiles revealed that compared to cells obtained in co-culture with neurons, microglia-like cells derived from a monoculture condition upregulate mRNA levels for Triggering Receptor Expressed On Myeloid Cells 2 (TREM2), which is reminiscent to the previously described disease-associated microglia. TREM2 is a risk gene for AD and an important regulator of microglia. In conclusion, we have developed an efficient method to generate monocultured microglia-like cells from iPSC.